Kathryn Anne Bowman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Fc | 1 | 2023 | 539 | 0.690 |
Why?
|
Viral Vaccines | 1 | 2022 | 595 | 0.560 |
Why?
|
Antibodies | 2 | 2023 | 2426 | 0.530 |
Why?
|
Mycobacterium tuberculosis | 3 | 2024 | 1931 | 0.270 |
Why?
|
Tuberculosis | 3 | 2024 | 2029 | 0.240 |
Why?
|
Immunoglobulin Isotypes | 1 | 2023 | 158 | 0.220 |
Why?
|
Immunity, Humoral | 3 | 2022 | 612 | 0.200 |
Why?
|
Saponins | 1 | 2021 | 47 | 0.190 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.160 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 167 | 0.160 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3210 | 0.160 |
Why?
|
Antibodies, Bacterial | 1 | 2024 | 1480 | 0.150 |
Why?
|
Antibodies, Neutralizing | 3 | 2022 | 2005 | 0.150 |
Why?
|
Immunity | 1 | 2023 | 1002 | 0.150 |
Why?
|
Toll-Like Receptor 2 | 1 | 2018 | 348 | 0.130 |
Why?
|
Protein Processing, Post-Translational | 1 | 2023 | 1969 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 865 | 0.120 |
Why?
|
Vaccination | 3 | 2022 | 3433 | 0.120 |
Why?
|
Interleukin-2 | 1 | 2018 | 1892 | 0.100 |
Why?
|
Disease Progression | 2 | 2024 | 13643 | 0.080 |
Why?
|
South Africa | 2 | 2024 | 1870 | 0.070 |
Why?
|
Membrane Glycoproteins | 1 | 2018 | 3710 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2022 | 12813 | 0.070 |
Why?
|
AIDS Vaccines | 1 | 2013 | 896 | 0.070 |
Why?
|
HIV | 1 | 2013 | 1587 | 0.060 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 1813 | 0.060 |
Why?
|
Macaca mulatta | 2 | 2022 | 2362 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 2 | 2023 | 2589 | 0.050 |
Why?
|
HIV Infections | 2 | 2023 | 17492 | 0.050 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2021 | 359 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 140 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 4403 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2021 | 445 | 0.040 |
Why?
|
Antibody Formation | 1 | 2024 | 1393 | 0.040 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 285 | 0.040 |
Why?
|
Viremia | 1 | 2022 | 715 | 0.040 |
Why?
|
Primates | 1 | 2021 | 523 | 0.040 |
Why?
|
Mycobacterium bovis | 1 | 2018 | 148 | 0.040 |
Why?
|
Viral Load | 2 | 2020 | 3374 | 0.040 |
Why?
|
Fatal Outcome | 1 | 2020 | 1841 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6347 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2023 | 3164 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2655 | 0.030 |
Why?
|
Humans | 10 | 2024 | 768369 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2018 | 831 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2020 | 12450 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2728 | 0.030 |
Why?
|
Haplotypes | 1 | 2018 | 2723 | 0.030 |
Why?
|
Epitope Mapping | 1 | 2013 | 299 | 0.020 |
Why?
|
Virus Latency | 1 | 2013 | 359 | 0.020 |
Why?
|
Sex Factors | 1 | 2024 | 10647 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4570 | 0.020 |
Why?
|
Nanoparticles | 1 | 2021 | 1986 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2013 | 822 | 0.020 |
Why?
|
Male | 6 | 2024 | 364761 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9359 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18477 | 0.020 |
Why?
|
Adult | 4 | 2024 | 223528 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1786 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 60038 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2013 | 1898 | 0.010 |
Why?
|
Animals | 3 | 2022 | 169424 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2013 | 6527 | 0.010 |
Why?
|
Female | 4 | 2024 | 396926 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13447 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41782 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10269 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11928 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17637 | 0.010 |
Why?
|
Middle Aged | 3 | 2020 | 223406 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 4613 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 16023 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18047 | 0.010 |
Why?
|
Infant | 1 | 2018 | 36496 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 89163 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 59679 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 81835 | 0.010 |
Why?
|
Mice | 1 | 2018 | 82051 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39429 | 0.010 |
Why?
|
Aged | 1 | 2020 | 171514 | 0.000 |
Why?
|